$header$
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer

Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD

Abstract

Lung cancer remains the leading cause of cancer-related mortality in the United States. Most patients are diag- nosed with advanced disease, and while progress has been made in targeted therapy, very few changes in the platinum backbone have been made for those patients without actionable mutations or PD-L1 positivity. The utilization of immunotherapy in advanced non–small cell lung cancer (NSCLC) has completely altered the approach to treating this disease. Within less than two years, multiple agents have been FDA approved for the treatment of second-line therapy in metastatic NSCLC. Even more recently, a PD-1 antibody was approved for the first-line treatment of metastatic NSCLC in patients whose tumors have ≥50% PD-L1 expression. Multiple immunotherapeutics are being evaluated in combina- tions, sequences, and various stages in the treatment of all lung cancer. These immunotherapeutic advances have shifted a long-term paradigm in lung cancer treat- ment.

AJHO. 2016;12(11):4-8

Background

Lung cancer is the leading cause of cancer-related mortality in the United States1. Most patients with newly diagnosed non–small   cell lung cancer (NSCLC) have incurable disease. For decades, standard first-line treatment for metastatic NSCLC (mNSCLC)  has been platinum-doublet chemotherapy with anticipated response rates (RR) of about 30% and median overall survivals (mOS) of 10 to 12 months.2 Second-line chemotherapy with single-agent docetaxel has anticipated RR around 5% to 10%   with mOS of 7 months.3 The identification of driver mutations such as EGFR, ALK and ROS1 has led to the approval of multiple agents targeting these specific tumor alterations, resulting in improved RR and even mOS with fewer toxicities when compared with chemotherapy. Acquired resistance limits next-line treatment options. Additionally, the frequency of these mutations is low   and broader applications of novel interventions for all  NSCLC has been prioritized.

The capacity of the host immune system to disrupt tumors is  not a new concept. However, prior immunological approaches to the treatment of lung cancer were not successful. With the intro- duction of checkpoint inhibitors, immunotherapy re-emerged as a potential intervention in lung cancer.

Programmed cell death 1 (PD-1) is a type I transmembrane protein expressed on the surface of activated T cells. When PD-1 binds to one of its ligands (PD-L1 or PD-L2), T-cell activity is downregulated. Tumor cells can express PD-L1, and interaction with PD-1 on T cells can enable tumor growth via immune evasion. New immunotherapies block the binding of PD-1 and PD-L1, allowing ongoing activation of T  cells.

Within 18 months, three different checkpoint inhibitors were FDA-approved with multiple indications in mNSCLC (Table 1). These unprecedented advances have led to a completely different approach to mNSCLC treatment.
 

First-line Treatment

Although different immunotherapies had already proven similar benefits in the second-line setting, phase 3 data on two agents in the first-line treatment of mNSCLC yielded very different  results.

KEYNOTE-024 is the pivotal trial that led to the first FDA approval of immunotherapy in first-line treatment of patients  with mNSCLC.4 Of 1934 patients screened, 305 with previously untreated mNSCLC with ≥50% PD-L1 expression on tumor cells by immunohistochemistry (IHC) and without EGFR  mutation or ALK rearrangement were randomized to pembrolizumab (Keytruda) 200 mg every 3 weeks versus investigator-choice plati- num-based doublet chemotherapy.

Patients in control arm could cross over to pembrolizumab at progression. Progression free survival (PFS), the  primary endpoint, was 10.3 months with pembrolizumab versus 6 months with chemotherapy, including 43.7% of patients who crossed   over to pembrolizumab (HR, 0.50; P <.001). Six-month OS was 80.2% with pembrolizumab compared with 72.4% with chemo- therapy (HR, 0.60; P <.005). Overall RR was also higher with pembrolizumab (45% versus 28%), and median duration of response (DoR) was longer with pembrolizumab (not reached ver- sus 6.3 months). Pembrolizumab was better tolerated with  27% of patients experiencing grade 3 to 5 treatment-related toxicities compared with 53% of patients receiving chemotherapy. Based   on these results, the FDA approved pembrolizumab in October 2016 as first-line treatment in patients with mNSCLC whose tumors have ≥50% PD-L1 expression and no EGFR or ALK genomic tumor aberrations. These significant results changed the multi-decade-old treatment paradigm in first-line mNSCLC, offer- ing an effective and tolerable treatment for approximately 30% of the patients with high PD-L1
expressing  tumors.

Nivolumab, an IgG4 anti–PD-1 monoclonal antibody, failed  to meet expectations in the same setting. CheckMate 026 ran- domized 541 patients for first-line treatment of mNSCLC with PD-L1-positive tumors (≥ 5% expression by IHC) to nivolumab   3 mg/kg every 2 weeks versus investigator-choice platinum-based doublet chemotherapy.5 The study did not meet its primary endpoint of PFS (4.2 months with nivolumab versus 5.9  months with chemotherapy; HR, 1.15; P = .25), including 60% of patients who crossed over to nivolumab. One-year PFS was 23.6% versus 23.2%, respectively. In patients with PD-L1 tumor  expression >5%, OS was 14.4 months with nivolumab versus 13.2  months with chemotherapy. Overall RR was not higher with nivolumab (26% versus 34%), although those who did respond, median DoR was longer with nivolumab (12.1 versus 5.7  months). Nivolumab was well tolerated with 18% grade 3/4 treatment-re- lated toxicities compared with 51% with chemotherapy. Interest- ingly and quite surprisingly, subgroup analysis of those patients with PD-L1 tumor expression ≥50% did not show significantly improved PFS or OS.

Other immunotherapeutics including anti-PD-L1 antibodies atezolizumab and durvalumab are being evaluated in first-line treatment for mNSCLC.

Second-line Treatment

Immune checkpoint inhibitors were first approved in mNSCLC  in the second-line setting. Currently two PD-1 inhibitors and one PD-L1 inhibitor are FDA-approved as second-line treatment with varied indications in mNSCLC.

Two large phase 3 randomized trials were conducted comparing nivolumab 3 mg/kg every 2 weeks to docetaxel 75 mg/m²  every 3 weeks in mNSCLC, one in squamous histology (CheckMate 017)6 and another in non-squamous histology (CheckMate 057).7 CheckMate-017 randomized 272 patients with squamous mNS- CLC with disease progression on platinum-based doublet chemo- therapy to either nivolumab or docetaxel. Primary endpoint OS was improved with nivolumab (9.2 versus 6 months; HR, 0.59; 95% CI 0.44-0.79). RR was higher with nivolumab, 20% versus 9%. Eighty-three percent of patients had quantifiable PD-L1 expression on archived tumor tissue. Expression of PD-L1 was neither prognostic nor predictive of efficacy in patients with squa- mous NSCLC. Nivolumab was well tolerated with 7% grade 3/4 toxicities compared with 55% in docetaxel group. Based on these results, in March 2015, FDA approved nivolumab for squamous mNSCLC with disease progression after first-line  chemotherapy.

CheckMate-057 randomized 582 patients with non-squamous mNSCLC whose disease failed platinum-based doublet chemo- therapy to nivolumab or docetaxel. Median OS, primary end- point, was prolonged with nivolumab compared with docetaxel (12.2 versus 9.4 months; HR, 0.73; 95% CI  0.59-0.89).

Nivolumab demonstrated superior 1-year and 18-month survival rates (51% versus 39% and 39% versus 23%, respective- ly). PD-L1 expression was measured on archived samples in 78%  of patients; unlike the squamous trial, PD-L1 expression was predictive of response to nivolumab with trend toward higher   RR as PD-L1 expression level increased. Nivolumab was well tolerated with 10% grade 3/4 toxicities compared with 54% with docetaxel. In October 2015, nivolumab received FDA approval for all patients with non-squamous mNSCLC whose disease progressed after first-line platinum-based  chemotherapy.

KEYNOTE-001 is a phase 1 study of 495 evaluable patients with mNSCLC to determine safety, side-effect profile, and anti- tumor activity of pembrolizumab.8 Unlike the CheckMate  trials, patients were required to have biopsy-proven PD-L1 expression  and previously untreated patients were also allowed to enroll. Overall RR was 19.4%, including RR of 18% in 394 previously treated patients and 24.8% in 101 previously untreated patients. Additionally, in 61 previously treated patients with ≥ 50% PD-L1 tumor expression, RR was 41%. In addition to the frontline,    FDA granted accelerated approval to pembrolizumab for the treat- ment of patients with mNSCLC whose tumors express PD-L1  on ≥50% of all cells with disease progression after platinum-contain- ing chemotherapy.

KEYNOTE-010 is a phase 2/3 study of 1034 patients with mNSCLC who received either pembrolizumab 2 mg/kg or 10 mg/kg or docetaxel 75 mg/m² every 3 weeks.9 Primary endpoints were OS and PFS, both in the total population and in patients  with ≥50% PD-L1 tumor expression. Median OS was significantly longer with pembrolizumab 2 mg/kg at 10.4 months (HR, 0.71; 95% CI, 0.58-0.88; P = .0008) and with pembrolizumab 10  mg/ kg at 12.7 months (HR, 0.61; 95% CI, 0.49-0.75; P <.0001)
compared with 8.5 months with docetaxel. Median PFS was not significantly different with either pembrolizumab 2 mg/kg (3.9 months) or pembrolizumab 10 mg/kg (4 months) compared with docetaxel (4 months). Among patients with ≥50% PD-L1 tumor expression, mOS was significantly longer with pembrolizumab 2 mg/kg at 14.9 months (HR, 0.54; 95% CI, 0.38-0.77; P =  .0002)
and pembrolizumab 10 mg/kg at 17.3 months (HR 0.50; 95%  CI 0.36-0.70; P <.0001) compared with 8.2 months with docetaxel. PFS was significantly longer with both pembrolizumab dosing groups (5 and 5.2 months) versus docetaxel (4.1 months). The researchers reported that pembrolizumab was well tolerated with 13% to 16% grade 3/4 treatment-related toxicities compared with 35% in the docetaxel group.

POPLAR10 is an open-label, phase 2 trial of 287 patients with mNSCLC who failed platinum-based chemotherapy randomized to atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks. Primary endpoint was met with OS of 12.6 months with atezoli- zumab versus 9.7 months with docetaxel (HR, 0.73; 95% CI, 0.53–0.99; P = .04). Patients were stratified based on percentage  of PD-L1-expressing tumor cells (TC) by IHC to TC3 ≥50%,  TC2 ≥5% and <50%, TC1 ≥1% and <5%, and TC0 <1% and percent- age of tumor-infiltrating immune cells (IC) to IC3 ≥10%,  IC2
≥5% and <10%, IC1 ≥1% and <5%, and IC0 <1%. Increasing improvement in OS was associated with increasing PD-L1 expres- sion. Atezoluzumab was well tolerated with 11% treatment-related grade 3/4 toxicities compared with 39% patients in the docetaxel group.

OAK,11 a randomized phase 3 study comparing atezolizumab with docetaxel in previously treated mNSCLC, confirmed the efficacy of atezolizumab seen in POPLAR. In the trial, 1225 patients stratified by PD-L1 status, prior chemotherapy regi- mens, and histology were randomized to atezolizumab 1200 mg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks.  Co-primary endpoints were OS in the entire study population and in a PD-L1- defined subgroup. Secondary endpoints included PFS, ORR, DoR and safety. Within 850 evaluable patients, mOS was 13.8 months with atezolizumab versus 9.6 months with docetaxel (HR, 0.74; 95% CI, 0.62-0.87; P = .0003). Survival was improved regardless    of PD-L1 expression levels, including in patients with no PD-L1 expression (TC0 and IC0) (HR, 0.82; 95% CI, 0.68– 0.98).  How- ever, there was pronounced benefit in patients with high PD-L1 expression (TC3 or IC3; HR, 0.41; 95% CI, 0.27– 0.64). The
benefit was consistent across histologic subgroups, smoking status, or baseline brain metastasis status. PFS was 2.8 versus 4.0 months, ORR was 13.6% versus 13.4%, and DoR was 16.3 versus 6.2 months for atezoluzumab versus docetaxel, respectively. Atezoli- zumab was well tolerated with 15% grade 3/4 toxicities compared with 43% in docetaxel group. Atezolizumab was approved by the FDA in October 2016 for treatment of mNSCLC progressing after platinum-containing chemotherapy irrespective of PD-L1  status.

Combination Treatment

Combination of immunotherapies such as PD-1/PD-L1 inhibitors with anti–CTLA-4 antibodies is being evaluated in both first- and next-line mNSCLC treatment. CheckMate-227 is an open-label randomized phase 3 trial investigating nivolumab or nivolumab  plus ipilumumab versus platinum-doublet chemotherapy in pa- tients with chemotherapy-naïve mNSCLC.12  MYSTIC is a   phase  3 trial evaluating durvalumab or durvalumab plus  tremelimumab versus chemotherapy as first-line therapy for mNSCLC.13 ARCTIC is a phase 3
trial evaluating durvalumab or tremelimumab alone or durvalum- ab plus tremelimumab versus chemotherapy in PD–L1–negative patients after at least 2 lines of chemotherapy.14

Another active area of research is combining immunotherapy with chemotherapy. Multiple ongoing trials are combining PD-1/ PD-L1 inhibitors or anti–CTLA-4 antibodies with chemotherapy. KEYNOTE-021 is a phase 2 multi-cohort study of pembrolizum-  ab combination therapies in mNSCLC.15 One cohort included treatment with four cycles of carboplatin-pemetrexed-pembroli- zumab followed by 24 months of pembrolizumab and indefinite pemetrexed maintenance or four cycles of carboplatin-pemetrexed followed by pemetrexed maintenance. RR was 55% with pem- brolizumab combination compared with 29% with chemother-  apy alone. RR was 57% in patients with <1% PD-L1 expression while RR was 80% in patients with ≥50% PD-L1  expression.
This treatment combination may be effective and tolerable and is being evaluated in a phase 2 study. Multiple phase 3, multicenter, randomized open-label studies are evaluating atezolizumab in com- bination with platinum-based chemotherapy or chemotherapy plus bevacizumab.16

Patient Selection

As indicated by the variability in results with different  agents and different PD-L1 tumor expression levels, appropriate identification of those patients most likely to garner responses   to those agents has been challenging. Regardless of assay or treating agent, high expression of PD-L1 is associated with   better response. However, PD-L1 may be an imperfect surrogate marker, as levels may be affected by intra-tumoral heterogeneity, dynamic expression, and assay variability. Interestingly, some pa- tients with no PD-L1 expression benefit from immunotherapy, suggesting another mechanism for response. Current evidence supports use of PD-L1 assay to guide management until a better biomarker is identified. Higher somatic nonsynonymous muta- tion burden in tumors was associated with better response to PD-L1 therapy than total mutation burden, indicating that neo- antigens likely associated with smoking might play an important role in response to therapy.17 Higher RRs were observed in patients with history of smoking across multiple studies1,6 with response rates up to 30% in patients with ≥5 pack-year tobacco history compared with no response in patients with <5 pack-year tobacco history.18 This continues to be an area of active research and debate.


Conclusion

The field of immunotherapy in lung cancer treatment is   evolving rapidly. Although lung cancer was previously thought   to be non-immunogenic, immunotherapy has shown durable responses with fewer side effects compared with traditional che- motherapy in treatment of mNSCLC. Although PD-L1 expres- sion has been associated with better response to therapy, other biomarkers such as mutational load need further investigation  for improved patient selection. Additional studies are underway evaluating combinations and sequences of checkpoint inhibitors with chemotherapy and other immunotherapies that will contin- ue to evolve the treatment landscape of lung  cancer.
 
Author affiliations: Srinivasa Sanikommu and Kathryn F. Mileham are with Levine Cancer Institute, Carolinas Health- Care System.
Author disclosures: Srinivasa Sanikommu and Kathryn F. Mileham report no conflicts of  interest.
Address correspondence to: Kathryn F. Mileham, MD, Chief, Section of Thoracic Medical Oncology, Levine Cancer Institute, Carolinas HealthCare System, 1021 Morehead Medical Drive, Suite 3100, Charlotte, NC 28204; telephone: (980) 442-0400, fax: (980) 442-9301; email: kathryn.mileham@carolinashealth- care.org.

 

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. doi:  10.3322/caac.21332.
  2. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell  lung cancer. N Engl J Med.  2002;346(2):92-98.
  3. Hanna N, Shepherd FA, Fossella FV, et al.   Randomized phase lll trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemother- apy. J Clin Oncol.  2004;22(9):1589-1597.
  4. Reck M, Rodriguez-Abreu D, Robinson A, et al. Pembroli- zumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
  5. Socinski MA, Creelan B, Horn L, et al. CheckMate 026:  A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand  1 (PD-L1)-positive NSCLC. Ann Oncol. 2016;27(suppl 6): vi552– vi587.
  6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell  lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/ NEJMoa1504627.
  7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell  lung cancer. N Engl J Med. 2015;373(17):1627-1639. doi: 10.1056/ NEJMoa1507643.
  8. Garon E, Rizvi NA, Hui R, et al. Pembrolizumab   for
    the treatment of non-small cell lung cancer. N Engl J   Med. 2015;372(21):2018-2028. doi: 10.1056/NEJMoa1501824.
  9. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7.
  10. Fehrenbacher L, Spira A, Ballinger M, et al. Atezoli- zumab versus docetaxel for patients with  previously treated non-small-cell lung cancer (POPLAR): a multi- centre, open-label, phase II randomized control  trial. Lancet. 2016;387(10030):1837-1846. doi:  10.1016/S0140-6736(16)00587-0.
  11. Barlesi F, Park K,Ciadiello J, et al. Primary analysis from OAK, a randomized phase III study comparing  atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol. 2016;27 (suppl 1): Abstract LBA44_PR.
  12. Hellman M, Ramalingam S, Reck M, et al. An open label randomized phase III trial of nivolumab or nivolumab   plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent  non-small cell lung cancer (NSCLC) (CheckMate 227). J Immunoth- er Cancer. 2015;3(suppl 2): P154.
  13. Peters S, Antonia S, Goldberg SB, et al. MYSTIC: a glob- al, phase 3 study of durvalumab (MEDI4736) plus tremelim- umab combination therapy or durvalumab monotherapy ver- sus platinum-based chemotherapy in the first-line treatment  of patients with advanced stage IV NSCLC. J Thorac   Oncol. 2016;11(suppl 4): S139-S140.
  14. Planchard D, Yokoi T, McCleod MJ, et al. A phase   III
    study of durvalumab (MEDI4736) with or without tremelim- umab for previously treated patients with advanced  NSCLC: rationale and protocol design of the ARCTIC   study. Clin Lung Cancer. 2016;17(3):232-236.e1. doi: 10.1016/j. cllc.2016.03.003.
  15. Langer C, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for  ad- vanced non-small cell lung cancer: a randomised, phase 2 cohort of open label KEYNOTE-021 study. Lancet  Oncol. 2016;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3.
  16. Mok T, Cappuzzo F, Jotte R, et al. Phase lll clinical trials   of atezolizumab in combination with chemotherapy in chemo- therapy negative patients with advanced NSCLC. Ann Oncol. 2015;26(suppl 9):103-106.
  17. Rizvi N, Hellmann M, Snyder A, et al.  Mutational landscape determinants sensitivity to PD-1 blockade in non- small cell lung cancer. Science. 2015;348(6230):124-128. doi: 10.1126/science.aaa1348.
  18. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death  1 antibody, BMS-936558, ONO-4538) in patients with previous- ly treated advanced non-small-cell lung cancer. J Clin  Oncol. 2015;33(18):2004-2012.  doi: 10.1200/JCO.2014.58.3708.
<>


Calendar of Events
Filter By